NEW YORK--(BUSINESS WIRE)--Pfizer announced that in patients with established heart disease, Lipitor® (atorvastatin calcium) 80 mg not only significantly reduced the relative risk of suffering a first cardiovascular event by 19 percent compared to Lipitor 10 mg but also provided a sustained reduction in the risk of a subsequent second, third, fourth, and fifth cardiovascular event, according to a subanalysis of the five-year Treating to New Targets (TNT) study.
